ACH-OMEPRAZOLE 20 MG — DIN 02416549
OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) : 20 MG · ACCORD HEALTHCARE INC · TABLET (DELAYED-RELEASE) · wholesale supply in Canada
Health Canada status: MARKETED
What is ACH-OMEPRAZOLE?
ACH-OMEPRAZOLE 20 MG contains OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02416549, held by ACCORD HEALTHCARE INC, supplied as TABLET (DELAYED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 22-May-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACH-OMEPRAZOLE used for?
ACH-Omeprazole (omeprazole magnesium delayed release tablets) is indicated in the treatment of conditions where a reduction of gastric acid secretion is required, such as: duodenal ulcer, gastric ulcer, NSAID-associated gastric and duodenal ulcers, reflux esophagitis, symptomatic gastroesophageal reflux disease (GERD), dyspepsia, Zollinger-Ellison syndrome, and eradication of Helicobacter pylori (H. pylori). It is also indicated in combination with clarithromycin and either amoxicillin or metronidazole, for the treatment of patients with peptic ulcer disease associated with Helicobacter pylori infection.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Omeprazole cost around the world?
Omeprazole is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 12 | 115 | AUD███.██ |
| Greece | producer price (ex-factory) | 92 | 92 | EUR███.██ |
| Morocco | PPV (public price) | 18 | 57 | MAD███.██ |
| Saudi Arabia | public | 41 | 56 | SAR███.██ |
| Bahrain | retail (max) | 24 | 48 | BHD███.██ |
| South Africa | single exit price | 33 | 41 | ZAR███.██ |
| Luxembourg | reimbursement | 32 | 32 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 19 | 31 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 8 | 23 | CZK███.██ |
| United Arab Emirates | public | 11 | 17 | AED███.██ |
| United Kingdom | hospital | 8 | 8 | GBP███.██ |
| Iceland | max wholesale | 4 | 4 | ISK███.██ |
524 pack listings across 302 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Omeprazole pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Omeprazole in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
27 holders have a Canadian DIN containing Omeprazole, across 57 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 6 | 2 | NOVO-OMEPRAZOLE, OMEPRAZOLE 20 MG, RATIO-OMEPRAZOLE, TEVA-OMEPRAZOLE | Sourceable in Canada |
| CHEPLAPHARM ARZNEIMITTEL GMBH | 4 | 2 | LOSEC, LOSEC MUPS | Sourceable in Canada |
| APOTEX INC | 3 | 2 | APO-OMEPRAZOLE, HEARTBURN CONTROL | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 3 | 1 | OMEPRAZOLE, OMEPRAZOLE-20 | Sourceable in Canada |
| ACCORD HEALTHCARE INC | 2 | 1 | ACH-OMEPRAZOLE, AHI-OMEPRAZOLE | Sourceable in Canada |
| SANIS HEALTH INC | 2 | 1 | OMEPRAZOLE, OMEPRAZOLE MAGNESIUM DELAYED RELEASE TABLETS | Sourceable in Canada |
| BIOMED PHARMA | 1 | 1 | BIO-OMEPRAZOLE | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP-OMEPRAZOLE DR | Sourceable in Canada |
| PRO DOC LIMITEE | 1 | 1 | OMEPRAZOLE | Sourceable in Canada |
| PHARMASCIENCE INC | 5 | 0 | OMEPRAZOLE, PMS-OMEPRAZOLE, PMS-OMEPRAZOLE DR | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 5 | 0 | OMEP, SANDOZ OMEPRAZOLE | No marketed DIN |
| ASTRAZENECA CANADA INC | 3 | 0 | LOSEC 10 MG, LOSEC CAPSULES 10MG, LOSEC CAPSULES 40MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 20 MG |
|---|---|
| Dosage form | TABLET (DELAYED-RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | 100 and 500 |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Omeprazole |
|---|---|
| ATC code | A02BC01 |
| AHFS class | 56:28.36 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02416549 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2416549 |
| Brand name | ACH-OMEPRAZOLE |
| Generic / active ingredient | OMEPRAZOLE (OMEPRAZOLE MAGNESIUM) : 20 MG |
| Market authorization holder | ACCORD HEALTHCARE INC |
| Health Canada schedule | Prescription |
| ATC code | A02BC01 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A02BC |
| Current status | MARKETED |
| Status date | 22-May-2024 |
| Original market date | 2013-12-05 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 57 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OMEPRAZOLE | 20 MG | CAPSULE (DELAYED RELEASE) | APOTEX INC | MARKETED | 02245058 |
| BIO-OMEPRAZOLE | 20 MG | TABLET (DELAYED-RELEASE) | BIOMED PHARMA | MARKETED | 02449927 |
| HEARTBURN CONTROL | 20 MG | CAPSULE (DELAYED RELEASE) | APOTEX INC | MARKETED | 02435683 |
| JAMP-OMEPRAZOLE DR | 20 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | 02420198 |
| LOSEC | 20 MG | CAPSULE (DELAYED RELEASE) | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | 00846503 |
| LOSEC MUPS | 20 MG | TABLET (DELAYED-RELEASE) | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | 02242462 |
| OMEPRAZOLE | 20 MG | CAPSULE (DELAYED RELEASE) | PRO DOC LIMITEE | MARKETED | 02339927 |
| OMEPRAZOLE | 20 MG | CAPSULE (DELAYED RELEASE) | SANIS HEALTH INC | MARKETED | 02348691 |
| OMEPRAZOLE-20 | 20 MG | CAPSULE (DELAYED RELEASE) | SIVEM PHARMACEUTICALS ULC | MARKETED | 02411857 |
| TEVA-OMEPRAZOLE | 20 MG | TABLET (DELAYED-RELEASE) | TEVA CANADA LIMITED | MARKETED | 02295415 |
2 · Same class — other molecules in ATC A02BC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Pantoprazole | ABBOTT-PANTOPRAZOLE · ACT PANTOPRAZOLE · AG-PANTOPRAZOLE · AG-PANTOPRAZOLE SODIUM · +37 more | 98 | 39 | Yes |
| Esomeprazole | APO-ESOMEPRAZOLE · APO-ESOMEPRAZOLE DELAYED-RELEASE · ESOMEPRAZOLE · ESOMEPRAZOLE DR · +14 more | 46 | 26 | Yes |
| Lansoprazole | APO-LANSOPRAZOLE · AVA-LANSOPRAZOLE · DOM-LANSOPRAZOLE · LANSOPRAZOLE · +15 more | 41 | 19 | Yes |
| Omeprazole | ACH-OMEPRAZOLE · AG-OMEPRAZOLE DR · AHI-OMEPRAZOLE · APO-OMEPRAZOLE · +31 more | 57 | 12 | Yes |
| Rabeprazole | ABBOTT-RABEPRAZOLE · AG-RABEPRAZOLE · APO-RABEPRAZOLE · DOM-RABEPRAZOLE EC · +15 more | 38 | 8 | Yes |
| Dexlansoprazole | APO-DEXLANSOPRAZOLE · DEXILANT · DEXLANSOPRAZOLE | 8 | 4 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A02B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A02BA | Cimetidine · Famotidine · Famotidine, Combinations · Nizatidine · Ranitidine · +1 more | 235 | 26 |
| A02BX | Alginic Acid · Pirenzepine · Sucralfate | 32 | 4 |
| A02BB | Misoprostol | 10 | 2 |
| A02BD | Bismuth Subcitrate,Tetracycline And Metronidazole · Lansoprazole, Amoxicillin And Clarithromycin | 3 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ACH-OMEPRAZOLE called?
The same molecule, Omeprazole, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| APO-Omeprazole | Latin | Australia |
| Omeprazole Sandoz | Latin | Australia |
| ACILOC | Latin | Bahrain, Saudi Arabia |
| Losec Tablets | Latin | Australia |
| Omepral | Latin | Australia, Morocco |
| Acimax Tablets | Latin | Australia |
| Maxor | Latin | Australia |
| Maxor EC Tabs | Latin | Australia |
| OMEPRAZOLE CAPS WGR | Latin | Australia |
| OMEPRAZOLE-WGR | Latin | Australia |
| Ozmep | Latin | Australia |
| Probitor | Latin | Australia |
| IXOR | Latin | Morocco |
| KALEST | Latin | Morocco |
| OMEGEN | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.